Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fludarabine
Drug ID BADD_D00914
Description Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Indications and Usage For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Marketing Status Not Available
ATC Code L01BB05
DrugBank ID DB01073
KEGG ID D07966
MeSH ID C024352
PubChem ID 657237
TTD Drug ID D0F2XQ
NDC Product Code Not Available
Synonyms fludarabine | 9H-purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- | F-ara-A | 2-fluoroadenine arabinoside | 9-beta-D-arabinofuranosyl-2-fluoroadenine
Chemical Information
Molecular Formula C10H12FN5O4
CAS Registry Number 21679-14-1
SMILES C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal impairment20.01.03.010--Not Available
Respiratory tract infection11.01.08.017; 22.07.07.0010.000533%Not Available
Bone marrow failure01.03.03.0050.002131%
Acute graft versus host disease12.02.09.002; 10.02.01.0280.001668%Not Available
Chronic graft versus host disease12.02.09.003; 10.02.01.0290.000347%Not Available
Cytopenia01.03.03.0120.000533%Not Available
Haematological malignancy16.21.01.002; 01.13.01.0030.001251%Not Available
Treatment failure08.06.01.0170.000139%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000208%Not Available
X-linked lymphoproliferative syndrome16.21.02.003; 11.05.10.005; 10.03.01.003; 03.17.01.002; 01.13.02.003--Not Available
Acute kidney injury20.01.03.0160.003197%
Posterior reversible encephalopathy syndrome17.13.02.0070.005861%
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.0050.000278%Not Available
Autoimmune haemolytic anaemia10.04.01.005; 01.06.01.0040.000799%Not Available
Immune thrombocytopenic purpura01.08.01.007; 10.04.01.0080.000347%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000973%
B precursor type acute leukaemia16.01.01.004; 01.10.01.0040.000139%Not Available
Richter's syndrome16.28.02.005; 01.15.02.0050.000347%Not Available
Metastatic squamous cell carcinoma16.16.01.0100.000139%Not Available
Graft versus host disease in skin12.02.09.031; 10.02.01.062; 23.07.04.0250.000533%Not Available
Graft versus host disease in liver12.02.09.029; 10.02.01.060; 09.01.07.0330.000533%Not Available
Clonal evolution16.32.03.0220.000533%Not Available
Acute graft versus host disease in skin23.07.04.020; 12.02.09.022; 10.02.01.0530.000799%Not Available
Invasive lobular breast carcinoma16.10.01.014; 21.05.01.0220.000533%Not Available
Graft versus host disease in gastrointestinal tract10.02.01.059; 12.02.09.028; 07.11.01.0270.000278%Not Available
Toxic leukoencephalopathy17.13.02.012; 12.03.01.0590.000347%Not Available
The 9th Page    First    Pre   9    Total 9 Pages